Qianghua Zhou

Dr. Steven Zhou is a Hematopathologist and Transfusion Medicine Specialist at North York General Hospital, where he serves as Medical Director of Transfusion Medicine. He holds the rank of Assistant Professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto.

Dr. Zhou completed his residency training at the University of Toronto and practices across the fields of bone marrow pathology, lymphoma pathology, and transfusion medicine. His clinical work focuses on the diagnosis and classification of hematologic malignancies, integrating morphology, immunophenotyping, and molecular genetic findings to support patient care.

His research interests include acute myeloid leukemia and its molecular characterization, lymphoid neoplasms and their pathogenesis, and transfusion safety and quality improvement. His academic work aims to advance the understanding of hematologic diseases and improve diagnostic accuracy and transfusion practices through translational and clinically relevant research.

Selected publications

Pandiri M, Stengel A, Zhang J, Wang P, Shao H, Velmurugan S, Jacob A, Symes E, Kaur A, Rojek A, Zhou Q, et al. Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study. J Clin Pathol. 2025;78(9):629–635.

Wangulu C, Bahrami Hezaveh E, Zarif M, Zhou Q, Lo W, Wei C, Sibai H, Chang H. Genomic profile and clinical outcomes in acute myeloid leukemia with monosomal karyotype. Int J Mol Sci. 2025;26(12):5845.

Wangulu C, Zhao D, Zhou Q, Wei C, Kumar R, Schimmer A, Chang H. Proposed refinement of the 2022 European LeukemiaNet adverse-risk group of AML patients using a real-world cohort. Cancers. 2025;17(9):1405.

Shi S, Zhou Q, Zhao D, Zarif M, Wei C, Sibai H, Chang H. Molecular genetic characterization of mixed-phenotype acute leukemia (MPAL) with BCR::ABL1 fusion. Leuk Res. 2025;151:107665.

Symes EO, Wang P, Sojitra P, Menon MP, Patel AA, Hasan F, Ghosh S, Roloff GW, Zhou Q, Findley A, et al. Somatic co-alteration signatures are prognostic in high-grade TP53-mutated myeloid neoplasms. Br J Haematol. 2025;206(4):1103–1108.

Yeung YW, Zhang Y, Zhou Q, Burack R. Neighborhood clustering analysis to define epithelial–stromal interface for tumor infiltrating lymphocyte evaluation. J Pathol Inform. 2025:100465.

Zhou J, Zhou Q. Current perspectives on novel therapies in acquired hemophilia A—a clinical practice review. J Lab Precis Med. 2025;10:9.

Chang YS, Lee YW, Liu CY, Othman J, Eckardt JN, Zhou Q, Tien FM, Lyu TW, Tsai XCH, Lin CC, et al. Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis. Haematologica. 2025.

Zhou Q, Chang H. Circulating composite B- and T-cell lymphoma. Blood. 2024;144(9):1027.

Zhou Q, Zhao D, Zarif M, Davidson MB, Minden MD, Tierens A, Yeung YW, Wei C, Chang H. A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria. Blood Adv. 2024;8(7):1760–1771.

Zhao D, Zhou Q, Zarif M, Eladl E, Wei C, Atenafu EG, Schuh A, Tierens A, Yeung YW, Minden MD, et al. AML with CEBPA mutations: a comparison of ICC and WHO-HAEM5 criteria in patients with ≥20% blasts. Leuk Res. 2023;134:107376.

Gong IY, Aminilari M, Landego I, Hueniken K, Zhou Q, Kuruvilla J, Hodgson DC. Comparative effectiveness of salvage chemotherapy regimens and CAR-T therapies in relapsed/refractory diffuse large B-cell lymphoma: a network meta-analysis. Leuk Lymphoma. 2023;64(10):1643–1654.

Zhao D, Zarif M, Zhou Q, Capo-Chichi JM, Schuh A, Minden MD, Atenafu EG, Kumar R, Chang H. TP53 mutations in AML are associated with dismal clinical outcome irrespective of frontline induction regimen and allogeneic transplantation. Cancers. 2023;15(12):3210.

Zhou Q, Zhao D, Zarif M, Yeung YWT, Richard-Carpentier G, Chang H. Impact of secondary-type mutations in NPM1-mutated AML. Eur J Haematol. 2023;111(1).

Zhou Q, Zhao D, Eladl E, Capo-Chichi JM, Kim DDH, Chang H. Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemia. Leuk Res. 2023;124:107002.